SecBot SecBot

IMMX

Immix Biopharma, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001873835 Biotech & Drug Discovery
$8.15 −0.20 (−2.40%)
Oct 23 4:00 PM ET · prev $8.35
Market cap
$692.2M
Small cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$24.50
+201% · range $17.40–30.00
Next earnings
Nov 5
in 10 days · EPS est. −$0.19
1 year
+140.4%
from $3.39 · Oct 27
30 days
−28.9%
from $11.47
52-week range
$3.03–14.47
−44% from high · low Nov 6
Avg volume 20D
1.63M
Sep 29 spike 5.76M
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read BEARISH 3 reports · 90 days
Balance 2 bearish · 1 bullish oldest → newest, height = score
Avg score ·High conf. 3/3 ·Next Earnings date, Nov 5, 2026
Strongest BULLISH Immix Biopharma reported an interim update from its Phase 2 NEXICART-2 trial showing an 89% (40/45) complete…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 22 added (1 new), 2 trimmed or exited. Largest new: Wellington Management Group $15.2M.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.172 → −$0.186 over 90 days. 0 up, 2 down in 30 days.

  • TrendDOWNTREND

    29% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$15.2M
in new stakes
FundMoveSharesValue
STATE STREET CORPDOUBLED2,996,935$30.9M
BlackRock, Inc.DOUBLED2,989,972$30.8M
VANGUARD CAPITAL MANAGEMENT LLCADD2,507,122$25.8M
UBS Group AGDOUBLED1,941,817$20.0M
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED1,739,919$17.9M
WELLINGTON MANAGEMENT GROUP LLPNEW1,473,409$15.2M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED1,201,097$12.4M
CITADEL ADVISORS LLCDOUBLED506,157$5.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy3Buy9Hold1Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +201%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 29, 2026Needham
MAINTAIN
MAINTAINBuy
Sep 15, 2026Mizuho
MAINTAIN
MAINTAINOutperform
Aug 11, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Aug 10, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 22, 2026Needham
INITIATE
INITIATEBuy
Jun 18, 2026B of A Securities
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
May 22, 2026
Adams Helen C.
Director
AWARD6,250 sh
May 22, 2026
Marquet Magda
Director
AWARD12,500 sh
May 22, 2026
CHANG NANCY T
Director
AWARD12,500 sh
May 22, 2026
BUCHAN JANE
Director
AWARD12,500 sh
May 22, 2026
Hsu Jason
Director
AWARD6,250 sh
May 22, 2026
Morris Gabriel S
CFO, President
AWARD500,000 sh
May 22, 2026
Chudnovsky Yekaterina
Director
AWARD12,500 sh
May 22, 2026
CHANG NANCY T
Director
AWARD6,250 sh

Earnings setup

Estimates
Nov 5
reports in 10 days
−$0.19
EPS estimate, this quarter
−8%
estimate change, 90 days
0↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.19-$0.21–-$0.17+1.5%$0.00
Next Q-$0.20-$0.26–-$0.17-2.9%$0.00
Current FY-$0.72-$0.80–-$0.51-0.2%$0.00
Next FY-$0.95-$1.45–-$0.20-10.7%$27.9M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 5, 2026 Other
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We
Sep 30, 2026 SEC
Immix Biopharma priced a $125 million underwritten offering of 11,363,637 shares at $11.00 per share, with net…
8-K — Impact 6/10
Sep 29, 2026 SEC
Immix Biopharma is offering 11,363,637 shares of common stock at $11.00 per share via an underwritten public offering…
424B5 — Impact 6/10
Sep 29, 2026 SEC
Immix Biopharma reported an interim update from its Phase 2 NEXICART-2 trial showing an 89% (40/45) complete response…
8-K — Impact 7/10
Jun 30, 2026 Inst.
STATE STREET CORP — DOUBLED
2,996,935 shares ($30.9M)
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
2,989,972 shares ($30.8M)
May 22, 2026 Insider
Adams Helen C. was granted 6,250 shares
Director
May 22, 2026 Insider
Marquet Magda was granted 12,500 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
IMMX Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Oct 5, 2026
Press release
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL…
Sep 30, 2026
Press release
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – – Financing includes leading U.S. biotechnology…
Sep 3, 2026
Trial readout
T-90d Trial Readout: NXC-201 CAR-T (Phase 2)
Trial: Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis Sponsor: Nexcella Inc. Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING…
Aug 6, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. ("Immix" or the…
Aug 6, 2026
Earnings date
IMMX Q2 2026 Earnings Scheduled — 2026-08-06

SecBot reports

5 filings · 1 press release · 1 bullish · 3 bearish · 1 neutral
All IMMX filing & press-release reports (6)